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Abstract
Background: Chronic kidney disease (CKD) is a devastating illness associated with increased mortality, reduced
quality of life, impaired growth, neurocognitive impairment and psychosocial maladjustment in children. There is
growing evidence of socioeconomic disparities in health outcomes among children with CKD. Patient navigators
are trained non-medical personnel who assist patients with chronic conditions journey through the continuum of
care and transit across different care settings. They help vulnerable and underserved populations to better
understand their diagnosis, treatment options, and available resources, guide them through complex medical
systems, and help them to overcome barriers to health care access. Given the complexity and chronicity of the
disease process and concerns that current models of care may not adequately support the provision of high-level
care in children with CKD from socioeconomically disadvantaged backgrounds, a patient navigator program may
improve the provision of care and overall health of children with CKD.
Methods: The NAV-KIDS2 trial is a multi-centre, staggered entry, waitlisted randomised controlled trial assessing the
health benefits and costs of a patient navigator program in children with CKD (stages 3–5, on dialysis, and with
kidney transplants), who are of low socioeconomic backgrounds. Across 5 sites, 210 patients aged from 3 to 17
years will be randomised to immediate receipt of a patient navigator intervention for 24 weeks or waitlisting with
standard care until receipt of a patient navigator at 24 weeks. The primary outcome is child self-rated health (SRH)
6-months after completion of the intervention. Other outcomes include utility-based quality of life, caregiver SRH,
satisfaction with healthcare, progression of kidney dysfunction, other biomarkers, missed school days, hospitalisations
and mortality. The trial also includes an economic evaluation and process evaluation, which will assess the cost-
effectiveness, fidelity and barriers and enablers of implementing a patient navigator program in this setting.
Discussion: This study will provide clear evidence on the effectiveness and cost-effectiveness of a new intervention
aiming to improve overall health and well-being for children with CKD from socioeconomically disadvantaged
backgrounds, through a high quality, well-powered clinical trial.
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Background
CKD is a devastating illness associated with increased
mortality, reduced quality of life, impaired growth, neu-
rocognitive impairment and psychosocial problems in
children. The overall annual mortality rate for children
on dialysis is 35 per 1000 population and is 30-fold
higher than children without CKD [1]. Such large
discrepancies in mortality rates remain despite medical
advances over the past two decades [1].
There is growing evidence of socioeconomic inequal-
ities in health among children with CKD [2, 3]. Our re-
cent work has reported that children with CKD of the
lowest and second lowest socioeconomic status (SES)
quartiles were at least three and two times respectively
more likely to experience poorer overall health com-
pared to the highest SES quartile [2]. Preliminary unpub-
lished data from the Kids with Chronic Kidney Disease
(KCAD) study suggest that poor health in children with
CKD is not only attributed to the direct influence of the
chronic illness but also reflects outcomes of the complex
pathway that defines equitable access to healthcare.
Socioeconomic disparities in health among children with
CKD are likely attributable to a myriad of different bar-
riers including patient-level, health system and provider
factors that extend beyond biological differences [4, 5].
There are many potential barriers related to health care
and may include the high costs of care, the dearth of
available services that are specific to the needs of chil-
dren with CKD and the lack of culturally competent care
in this vulnerable population [6].
Patient navigators are trained non-medical personnel
who assist patients with complex and/or chronic condi-
tions journey through the continuum of care and transit
across different care settings [7]. They help neglected
and underserved populations with chronic illness to bet-
ter understand their diagnoses, treatment options, and
available resources, help to guide them through complex
medical systems, and help them to overcome barriers to
health care access and bridge gaps in transitions of care.
In the context of cancer care, patient navigator programs
improve patients’ satisfaction with care and treatment
adherence [8]. Outside oncology, there is some evidence
supporting the use of patient navigator programs in chil-
dren with chronic conditions such as diabetes, asthma
and obesity, to facilitate improved access to care [9].
However, the benefits of patient navigators in paediatric
nephrology settings have not been assessed. There are
growing concerns that the current model of care in
paediatric nephrology may not adequately support the
provision of high-level care for children from socioeco-
nomically disadvantaged backgrounds. Given this, and
the complexity and chronicity of the disease process, we
hypothesize that a patient navigator program will lead to
improvement in the provision of care and overall health
of children with CKD and will be cost-effective.
The NAV-KIDS2 trial is a multi-centre, staggered
entry, waitlisted randomised controlled trial that as-
sesses the health benefits and costs of a patient navi-
gator program in children with chronic kidney disease
(CKD) stages 3–5, on dialysis (CKD-D) and with
kidney transplants (CKD-T), who are from low socio-
economic backgrounds. The trial design and research
plan are informed by extensive longitudinal observa-
tional and qualitative data from the Kids with CKD
(KCAD) study [10].
Key research question
In children with CKD (3–5), CKD-D and CKD-T and of
low SES backgrounds, does a patient navigator program
improve the overall health and well-being compared to
standard care?
Study objectives
Primary objective
To compare the self-rated health (SRH) of children with
CKD randomised to the intervention (patient navigator
program) arm and control (wait-listed) arm.
Secondary objectives
To compare the between group means of the secondary
end-points including utility-based quality of life, SRH of
the caregiver, caregivers’ satisfaction with healthcare,
progression of kidney dysfunction, other biomarkers
(kidney, liver and haematological function), the number
of hospitalisations and missed school days; and compare
the between group mortality rates. An additional
secondary objective is to assess the cost-effectiveness of
a patient navigator program in children with CKD
compared to standard care, based on the incremental
costs and benefits associated with implementation.
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Tertiary objectives
To assess the fidelity, satisfaction, facilitators and barriers
of a patient navigator program in children with CKD.
Methods
Study design
The NAV-KIDS2 trial is a multi-centre, staggered-entry,
waitlisted randomised controlled trial of a patient navi-
gator program in children with CKD. The rationale for
this design is that there is some evidence of health and
social benefits for patient navigator programs [9], and a
general expectation that the patient navigator program
will do good than harm in children with chronic illness.
As such, it would be unethical to withhold the interven-
tion from a proportion of the participants as in a trad-
itional parallel design. The waitlisted controlled design
has the benefit of allowing all eligible participants to
be enrolled and receive the same intervention for the
same duration of time, but with staggered entry at
different time points (different waves) such that
participants with delayed entry will serve as controls
[11]. It will also aid recruitment as all participants
will have the opportunity to access the intervention.
The trial schema is shown in Fig. 1.
Study setting
Participants will be recruited from 5 hospital sites across
Australia: The Children’s Hospital at Westmead; Sydney
Children’s Hospital, Randwick; Queensland Children’s
Hospital; Royal Children’s Hospital Melbourne; and
the Women’s and Children’s Hospital Adelaide. Re-
cruitment will be leveraged by our observational
KCAD study [10]. Currently, a total of 194 children
from the KCAD study are from low SES backgrounds.
Recruitment is therefore highly feasible as we will be
able to fulfil around 90% of our sample size by invit-
ing participants from the KCAD study alone. We will
also recruit new participants from the five largest
paediatric nephrology units in Australia.
Eligibility criteria
Inclusion criteria
To be eligible for the study, participants must satisfy all
of the following criteria.
Diagnosed with CKD (3–5) or CKD-D or CKD-T.
Aged 3–17 years (inclusive).
Low SES background. Low SES families are defined as
those satisfying any of the following criteria:
Weekly household income of less than the median
gross household income, $1250 (AUD) per week;
Poor or very poor self-perceived financial status;
Single parenting on social benefits;
Both parents are unemployed; or
Families living in public housing.
Exclusion criteria
Life expectancy of less than 12months.
Unable or unwilling to provide consent by the care-
giver (and child assent if the child is 16 years or over).
Consent process
Consent will be obtained by the trial coordinator or a
research assistant. For children under 16 years, a parent
or caregiver will sign the consent form on behalf of the
child. Children under 16 who are considered by the
investigator to be of requisite maturity to understand
the study requirements will be asked to assent and coun-
tersign the parent consent form. This will be determined
by the investigator on a case-by-case basis and will vary
with the level of maturity of the child participant. For
children aged 16 or 17 years, a parent or caregiver will
sign the parent consent form and the child will counter-
sign the parent consent form. For participants who do
not speak English, a phone interpreter service will be
used during the consent process.
Intervention
Navigators will be trained using a training program
developed for the study and will have support from an
existing patient navigator organisation (CanCare). The
navigator will work with patients, caregivers, and health
Fig. 1 Trial schema
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professionals to achieve better care and health for
patients through involvement in their social, community
and health organisational networks. It is a complex and
individualised intervention that will be tailored to the
needs of the patients and their families [12]. The naviga-
tor will follow a four-by-five matrix of tasks (identifica-
tion of task categories, facilitation tasks, identification of
networks, document and review) and networks (patient,
provider, non-clinical staff, supportive services, medical
records/electronic medical records). [13] Domains of
tasks in this study are further described below:
1. Identification of task categories for a specific patient
and family: navigating tasks may consist of identifying
and mitigating barriers with patients and healthcare pro-
fessionals. They may include telling (explaining where
and when a renal biopsy will be done), inquiring (asking
about the potential barriers, such as language barriers to
attend the next appointment after the biopsy), support-
ing (listening to the fears about the interventions) and
coaching (discussing the potential questions the patients
and families may wish to ask in the next appointment).
2. Facilitation for a specific patient and family: the
navigator may coordinate communication, seek advice
from non-medical and medical staff and help to bring
patients in for the appointments.
3. Identification of networks: the navigators will identify
all potential network interactions that are relevant to the
patients and their families. These may include: the
health service providers, the non-clinical staff (adminis-
trators and receptionist), and other social support ser-
vices such as social workers, community-based services,
transportation, and the maintenance of activities and
system tasks for patients.
4. Document and review: the navigator will record
their own actions (for example: steps taken with or on
behalf of the patients) and record other activities that
are relevant to the navigator role.
Participants who do not speak English will be paired
with a navigator who speaks a language they are com-
fortable speaking in or will have access to a phone inter-
preter service to translate their communications with
the navigator.
Randomisation and follow-up
The trial will be centrally coordinated at the Australa-
sian Kidney Trials Network (AKTN). Individuals who
meet the inclusion criteria and have given informed
written consent will be randomised with equal probabil-
ity to the intervention or the waitlisted controlled group,
via an independent central web-based system. The ran-
domisation sequence will be generated by a computer-
ized random number generator at the AKTN, using a
random permuted block design with randomly chosen
block sizes. Randomisation will therefore be kept
separate from recruitment (which will be conducted by
research personnel at each site), to maintain allocation
concealment. Randomisation will be stratified by CKD
stage and recruitment site, and permuted blocks will be
used for each stratum (combination of CKD stage and
site) to achieve balance. It is anticipated that 21 children
will be randomised to the intervention and waitlisted
arms at each site (42 children in total for each site). Five
different waves, across the five different sites, will be
progressively recruited, in concordance with the school
terms over the 12-month period. In the first wave (to be
conducted at the Children’s Hospital at Westmead),
children being randomised to the intervention arm will
receive the intervention (patient navigator program)
immediately after randomisation for 24 weeks. Assess-
ments will be conducted pre-intervention, 1-month and
3-months into the intervention, immediately post-inter-
vention, 6-months and 12-months after the intervention.
Children randomised to the wait-list arm will wait for
23 weeks but will receive standard care during the ‘wait--
period’. They will commence the intervention (patient
navigator program) in week 24. Assessments during the
‘wait-period’ will be conducted at baseline, 1-month and
3-months after randomisation and immediately
pre-intervention at 6-months. Similar to the intervention
arm, the waitlist-controlled arm will receive the inter-
vention for a period of 24 weeks. Assessments, using the
same methods, will be conducted at the same follow-up
time points as per the intervention arm. The other four
waves (at the four other recruiting sites) will occur se-
quentially at the beginning of each school term (3
months apart). The schedule for assessments for each
group is shown in Table 1 (immediate treatment group)
and Table 2 (waitlisted group).
Outcome measures
The primary study end-point is SRH of the child 6
months after the completion of the intervention (i.e.
6-months post-treatment). SRH, a patient-reported
health outcome, is a validated composite measure of glo-
bal health status [14]. It is a broad and holistic measure
that accommodates the World Health Organisation
(WHO) defined concept of health [15]. SRH is also a
stable measure of health over time. [16] Prior studies
have shown that children (from age 8 onwards) can
accurately communicate their health symptoms in a
meaningful way and can provide valuable insights into
their own health [17]. Below the age of 8 years, children
may have difficulty interpreting and understanding the
response categories. As such, parent-rated health of the
child will be used as a proxy for children between the
ages of 3 to 7 years. Parent-rated health has been validated
for use in young children (as young as pre-schoolers).
Recent work indicates that child self-rated health and
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parental ratings of the child’s overall health are associated
with the child’s physical and mental health [16, 18, 19].
The secondary end-points are the mean differences in
the SRH of the child and caregiver, utility-based quality of
life (QOL) estimates, progression of kidney dysfunction
calculated using the modified Schwartz creatinine-based
formula [20] for the estimated glomerular filtration rate
(eGFR), other biomarkers (urea, albumin, bilirubin, ala-
nine transaminase, alkaline phosphatase, gamma glutamyl
transferase, haemoglobin, white cell count, platelets),
caregivers’ satisfaction with healthcare, the number of hos-
pitalisations and missed school days, direct health-care
costs and mortality rates between the intervention and the
waitlisted controlled arms, up to 12-months after the
completion of treatment. Serum creatinine and other
biomarkers have been included to consider the impacts of
the intervention on kidney, liver and haematological func-
tion, since these outcomes may be affected by changes in
quality of care and adherence as a result of the interven-
tion. All outcome domains being considered in the study
are shown in Fig. 2 and all timepoints for outcome assess-
ments are shown in Table 1 and Table 2.
The outcome assessors and data analysts will be
blinded to treatment allocation, although blinding will
not be feasible for the children, caregivers or clinicians
and other researchers involved in study management.
Utility-based QOL will be assessed using the Health
Utility Index (HUI-3) [21], which will be completed by
the parent for children aged 3–7 years and by the child
for those aged 8 years and above. Serum creatinine and
other biomarkers (urea, albumin, bilirubin, alanine trans-
aminase, alkaline phosphatase, gamma glutamyl transfer-
ase, haemoglobin, white cell count, platelets) will be
measured from blood samples. Caregiver satisfaction
with the healthcare their child receives will be assessed
with a questionnaire covering issues such as caregivers’
perceived access to care and their confidence in navigat-
ing the healthcare system. All-cause, cardiovascular
(CV) and non-CV mortality up to 12-months after com-
pletion of treatment will be obtained using data linkage
with the National Death Index, maintained by the
Australian Institute and Health and Welfare (AIHW).
CKD-related outcomes up to 12-months post-treatment
among those on dialysis and with kidney transplants will
Table 1 Schedule of assessments for immediate treatment group
Screen Random Treat (1mo) Treat (3mo) End treat (6mo) Post-treat (6mo) Post-treat (12mo)
Day 0 28 84 168 336 504
Eligibility Criteria x
Demographics x
CKD Information x x x x x x
Medical History x x x x x x
Physical Examination x x x x x x
Bloods x x x x
Immunosuppressive Medications x x x x x x
Concomitant Medications x x x x x x
SRH (Child and Caregiver) x x x x x x
Educational Background x
School Absenteeism x x x x x x
HUI Questionnaire x x x x x x
Caregiver Satisfaction
Questionnaire (Caregiver)
x x x x x x
Patient Navigator Satisfaction
Questionnaire (Caregiver)
x x x
Adverse events x x x x x
Hospitalisation x x x x x
Data linkage (NDI, ANZDATA,
MBS, PBS)
x
Qualitative interviews/
questionnaires (subset
of participants only)
x x x x
Abbreviations. CKD: Chronic kidney disease, SRH: Self-rated health, HUI: Health utilities index, NDI: National death index, ANZDATA: Australia and New Zealand
Dialysis and Transplant Registry, MBS: Medicare Benefits Schedule, PBS: Pharmaceutical Benefits Scheme
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be obtained via data linkage (at 12months after comple-
tion of treatment) with the Australia and New Zealand
Dialysis and Transplant (ANZDATA) registry. Healthcare
resource use will be estimated using parent-reported hos-
pitalisations and linked Medicare Australia data for out-
patient healthcare use (including drug costs from the
Pharmaceutical Benefit Scheme (PBS) and healthcare
costs from the Medicare Benefits Schedule (MBS)). Costs
will be estimated by applying diagnosis-related groups
(DRG) or Medicare unit costs and will also include the
costs of the patient navigator program. Healthcare costs
for the intervention and control groups will be calculated
for the following time points: 3 months into treatment,
immediately post-treatment, 6 months post-treatment and
12months post-treatment.
Trial infrastructure
The trial will be centrally coordinated at the Australa-
sian Kidney Trials Network (AKTN). The trial will be
overseen by a Steering Committee, consisting of investi-
gators from the recruiting sites and two consumer repre-
sentatives. The committee will have two teleconferences
before study initiation and teleconferences quarterly
during study recruitment and follow-up. The data safety
monitoring board (DSMB), consisting of clinical, statis-
tical as well as clinical trial experts, will have the respon-
sibility for monitoring of adverse events and will ensure
the safety of children and families is protected.
Economic evaluation
An economic evaluation will be conducted to determine
the incremental costs and benefits of a patient navigator
program for improving the overall health of children
with CKD compared to standard care. Initially, a
within-trial economic evaluation will be conducted,
which will be extended to a modelled evaluation over a
longer time horizon, using a patient-level simulation
model. Data sources including the utility-based QOL es-
timates to generate quality adjusted life years (QALYs),
all other primary and secondary outcomes such as the
proportion of participants reporting better overall health,
and costs generated from the trial will be included in the
evaluation. We will take a healthcare funder perspective.
Therefore, costs will include all intervention costs and
all healthcare resource use over the trial duration,
including inpatient admissions, ED presentations and
Table 2 Schedule of assessments for waitlisted group
Screen Random Wait
(1mo)
Wait
(3mo)
Start
treat
Treat
(1mo)
Treat
(3mo)
End treat
(6mo)
Post-treat
(6mo)
Post-treat
(12mo)
Day 0 28 84 168 196 252 336 504 672
Eligibility Criteria x
Demographics x
CKD Information x x x x x x x x x
Medical History x x x x x x x x x
Physical Examination x x x x x x x x x
Bloods x x x x x
Immunosuppressive Medications x x x x x x x x x
Concomitant Medications x x x x x x x x x
SRH (Child and Caregiver) x x x x x x x x x
Educational Background x
School Absenteeism x x x x x x x x x
HUI Questionnaire x x x x x x x x x
Caregiver Satisfaction
Questionnaire (Caregiver)
x x x x x x x x x
Patient Navigator Satisfaction
Questionnaire (Caregiver)
x x x
Adverse events x x x x x x x x
Hospitalisation x x x x x x x x
Data linkage (NDI, ANZDATA,
MBS, PBS)
x
Qualitative interviews/ questionnaires
(subset of participants only)
x x x x
Abbreviations. CKD: Chronic kidney disease, SRH: Self-rated health, HUI: Health utilities index, NDI: National death index, ANZDATA: Australia and New Zealand
Dialysis and Transplant Registry, MBS: Medicare Benefits Schedule, PBS: Pharmaceutical Benefits Scheme
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outpatient resource use. Both costs and benefits will be
discounted at 5% per year. An incremental cost per
additional patient avoiding fair/poor health, and incre-
mental cost per QALY gained in the intervention group,
compared to the wait-listed group will be calculated with
results plotted on a cost-effectiveness plane. We will use
a patient level microsimulation model to examine costs and
outcomes over a longer time horizon. A cost-effectiveness
acceptability curve will be plotted to show the probability at
which an intervention is considered cost-effective, for a
given willingness to pay threshold.
Process evaluation
We will use a mixed methods approach to assess the
barriers and enablers for acceptance and uptake of the
program. The process evaluation will be conducted and
reported in accordance with Medical Research Council
guidance [22]. All participating caregivers will complete
the Patient Navigator Satisfaction Questionnaire at three
time points (1month into the intervention, 3months into
the intervention and immediately post-intervention), to
assess their perception of the intervention over time. In
addition, qualitative semi-structured interviews and ques-
tionnaires will be conducted by trained research personnel
with a purposive sample of children and family members
(min. n = 30) prior to the intervention, 3months into the
intervention, immediately post-intervention, and 6months
post-intervention. The topics will include: acceptance of
the navigator program; perceived barriers, challenges and
enablers for implementation; and the perceived benefits
and harms of the intervention. Key questions will also be
used to assess intervention fidelity regarding perceptions
of care received by the participants. Assessment of inter-
vention fidelity across the sites will also be carried out
through key-informant interviews of study staff (n = 30
interviews with navigators and healthcare professionals).
Questioning will also assess barriers and enablers to
program sustainability (short and long-term) and imple-
mentation of the intervention into standard care.
Sample size calculation
The sample size was calculated for the analysis of the
5-point Likert scale of the SRH of the child (and
parent-rated health for younger children) using logistic
regression. Assuming a dropout rate of 20%, a total of
210 children (105 in each arm) will be required for a
final sample of 166 patients. This sample size will allow
us to detect an odds ratio (OR) of 2.3, with approxi-
mately 80% power and a significance level of 0.05. Data
from the KCAD study indicated the OR of children from
the lowest SES quartile reporting poor and fair health
(compared with good, very good and excellent health)
was at least 2.08 [2]. Therefore, an OR of 2.3 is a clinic-
ally significant change in SRH with the proposed
intervention.
Statistical analyses
All data will be analysed according to the intention to
treat principle. The primary outcome, SRH of the child
between the intervention and waitlisted groups at 6
months post-treatment, will be compared using logistic
regression modelling. The second consecutive wave will
also allow for a pre and post analysis. We will use robust
standard errors to account for clustering within centres.
In addition, we will analyse the longitudinal change in
SRH up to 12-months after the intervention, using a
mixed model. The degree of change in SRH over the
various time points will also be examined for association
with key baseline characteristics of the participants such
as age, gender, CKD stage, by examining the time
Fig. 2 Outcome domains to be assessed
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interaction with these variables. Secondary endpoints
(continuous and count data) such as number of hospita-
lisations, utility-based QOL, caregiver satisfaction and
number of missed school days will be analysed using
Poisson regression to compare the difference between
the intervention and waitlisted groups. Subgroup ana-
lyses based on the different waves (i.e. the recruiting
sites) and CKD stage will also be conducted. Time to
event analyses will be used to estimate the rate of death
between the intervention and waitlisted groups using
Cox proportional hazards model, stratified by CKD stage
at the time of randomisation. A p-value of 0.05 will be
used to indicate statistical significance.
Discussion
Children with CKD suffer from significant physical,
cognitive and psychological complications. Apart from
reduced life expectancy and QOL, they are confronted
with a diverse range of adverse health and social out-
comes. The NAV-KIDS2 trial will provide clear evidence
of the effectiveness and cost-effectiveness of a new inter-
vention, through a high quality, well-powered clinical
trial. It is informed by extensive observational and quali-
tative data from the KCAD study that highlight the
current research gaps. This trial also has a number of in-
novative features. It is enriched by restricting the partici-
pants to those of low SES backgrounds, as prior work
has shown that patient navigation interventions focused
on communities-at-risk demonstrated a much greater
impact of patient navigation [7]. The staggered entry,
wait-listed controlled trial design not only ensures trial
efficiency, but also allows adjustment for other external
seasonal events, which are potential confounders to the
intervention effects. As the infrastructure for the
program will be developed during course of the trial, if
proven effective, the navigator program can be rapidly
implemented into clinical care.
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